<DOC>
	<DOCNO>NCT00003860</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat patient small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility administration intensive chemotherapy ifosfamide , carboplatin , etoposide follow peripheral blood stem cell support patient small cell lung cancer . II . Determine rate duration response patient treatment . III . Determine progression free overall survival patient . OUTLINE : This open label , multicenter study . Patients receive 4 course intensive chemotherapy consist ifosfamide IV 24 hour carboplatin IV 1 hour day 1 etoposide IV 1 hour day 1 2 . Filgrastim ( G-CSF ) administer subcutaneously begin day 2 continue blood cell count recover . Courses repeat every 14 day . Peripheral blood stem cell ( PBSC ) collect course 1 . PBSC reinfused day 3 course 2 3 . Patients experience complete response receive prophylactic cerebral irradiation day 71 . Patients follow every 2 month 5 year . PROJECTED ACCRUAL : A total 36 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven small cell lung cancer Good prognosis Manchester scale , 2 follow high risk factor : Karnofsky le 60 % Hyponatremia ( low sodium ) Alkaline phosphatase least 1.5 time upper limit normal ( ULN ) LDH great ULN No symptomatic CNS metastasis require corticosteroid PATIENT CHARACTERISTICS : Age : 18 60 Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : Neutrophil count least 2,000/mm3 Platelet count least 125,000/mm3 Hepatic : See Disease Characteristics Bilirubin less 1.25 time upper limit normal ( ULN ) SGOT/SGPT le 1.25 time ULN Renal : Creatinine le ULN Cardiovascular : LVEF least 50 % No myocardial infarction within 5 year No uncontrolled cardiac disease Pulmonary : No severe chronic obstructive pulmonary disease Other : No neurological symptom great grade 2 No severe psychoses No concurrent medical problem No active infection HIV negative No allergy E. coli derive product No prior malignancy within 5 year except basal cell skin cancer , carcinoma situ cervix , lung respiratory cancer remission Not pregnant nursing PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 1999</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>